At a glance
Geospatial distribution
All territories with background
All territories without background
France (mainland)
Global Network analyses
Cluster start date is defined as join date when the 3rd participant
joins clusters. Not terribly important in our analysis, more important
in time-to-event analyses.
\[
NormalizedClusterGrowth_{PastYear} =
\frac{{ClusterGrowth}_{PastYear}}{\sqrt{ClusterSize}_{PastYear}}
\]
To account for the size of the cluster, I normalized cluster growth
by the square root of cluster size. For example, the cluster size for a
given cluster in the past year is the size of the cluster at the
beginning of the year, before any any have been added.
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 2,295/13,538, i.e. 17%.
Cluster size and composition
Demographics by clustering status
| Characteristic |
Overall
N = 13,538 |
Clusters size ≥3
N = 1,363 |
Singletons
N = 12,175 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
4,034 (30%) |
107 (7.9%) |
3,927 (32%) |
|
| Male |
9,392 (69%) |
1,247 (91%) |
8,145 (67%) |
|
| Transgender F/M |
2 (<0.1%) |
0 (0%) |
2 (<0.1%) |
|
| Transgender M/F |
110 (0.8%) |
9 (0.7%) |
101 (0.8%) |
|
| Age |
51 (40, 59) |
42 (33, 53) |
51 (41, 60) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
351 (2.6%) |
68 (5.0%) |
283 (2.3%) |
|
| ≥25-<35 |
1,699 (13%) |
313 (23%) |
1,386 (11%) |
|
| ≥35-<45 |
2,759 (20%) |
377 (28%) |
2,382 (20%) |
|
| ≥45-<55 |
3,402 (25%) |
322 (24%) |
3,080 (25%) |
|
| ≥55-<80 |
5,154 (38%) |
275 (20%) |
4,879 (40%) |
|
| ≥80 |
173 (1.3%) |
8 (0.6%) |
165 (1.4%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
2,445 (20%) |
61 (4.8%) |
2,384 (22%) |
|
| WHO Americas |
725 (5.9%) |
33 (2.6%) |
692 (6.3%) |
|
| WHO Eastern Mediterranean |
283 (2.3%) |
20 (1.6%) |
263 (2.4%) |
|
| WHO Europe |
8,684 (71%) |
1,150 (91%) |
7,534 (69%) |
|
| WHO South-East Asia |
43 (0.4%) |
1 (<0.1%) |
42 (0.4%) |
|
| WHO Western Pacific |
72 (0.6%) |
2 (0.2%) |
70 (0.6%) |
|
| Regions francaises |
|
|
|
|
| Auvergne-Rhône-Alpes |
303 (2.2%) |
23 (1.7%) |
280 (2.3%) |
|
| Bourgogne-Franche-Comté |
18 (0.1%) |
3 (0.2%) |
15 (0.1%) |
|
| Bretagne |
1,256 (9.3%) |
102 (7.5%) |
1,154 (9.5%) |
|
| Centre-Val de Loire |
26 (0.2%) |
4 (0.3%) |
22 (0.2%) |
|
| Corse |
34 (0.3%) |
2 (0.1%) |
32 (0.3%) |
|
| Grand Est |
12 (<0.1%) |
0 (0%) |
12 (<0.1%) |
|
| Guadeloupe |
645 (4.8%) |
47 (3.4%) |
598 (4.9%) |
|
| Guyane française |
8 (<0.1%) |
0 (0%) |
8 (<0.1%) |
|
| Hauts-de-France |
29 (0.2%) |
3 (0.2%) |
26 (0.2%) |
|
| Île-de-France |
160 (1.2%) |
12 (0.9%) |
148 (1.2%) |
|
| Martinique |
922 (6.8%) |
99 (7.3%) |
823 (6.8%) |
|
| Mayotte |
1 (<0.1%) |
0 (0%) |
1 (<0.1%) |
|
| Normandie |
690 (5.1%) |
53 (3.9%) |
637 (5.2%) |
|
| Nouvelle-Aquitaine |
154 (1.1%) |
24 (1.8%) |
130 (1.1%) |
|
| Occitanie |
3,626 (27%) |
428 (31%) |
3,198 (26%) |
|
| Pays de la Loire |
2,863 (21%) |
260 (19%) |
2,603 (21%) |
|
| Provence-Alpes-Côte-d'Azur |
2,787 (21%) |
302 (22%) |
2,485 (20%) |
|
| Réunion |
4 (<0.1%) |
1 (<0.1%) |
3 (<0.1%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
12,295 (91%) |
1,042 (76%) |
11,253 (92%) |
|
| Oui |
1,243 (9.2%) |
321 (24%) |
922 (7.6%) |
|
| Transmission risk |
|
|
|
<0.001 |
| Bisexual |
737 (5.4%) |
113 (8.3%) |
624 (5.1%) |
|
| Blood |
237 (1.8%) |
12 (0.9%) |
225 (1.8%) |
|
| Heterosexual |
5,786 (43%) |
249 (18%) |
5,537 (45%) |
|
| IDU |
887 (6.6%) |
36 (2.6%) |
851 (7.0%) |
|
| Mother to child transmission |
221 (1.6%) |
1 (<0.1%) |
220 (1.8%) |
|
| MSM |
5,028 (37%) |
918 (67%) |
4,110 (34%) |
|
| Others |
81 (0.6%) |
5 (0.4%) |
76 (0.6%) |
|
| Unknown |
561 (4.1%) |
29 (2.1%) |
532 (4.4%) |
|
| Drug use |
|
|
|
<0.001 |
| Current |
1,228 (10%) |
221 (18%) |
1,007 (9.2%) |
|
| None |
6,765 (56%) |
616 (49%) |
6,149 (56%) |
|
| Past |
1,310 (11%) |
135 (11%) |
1,175 (11%) |
|
| Sometimes |
575 (4.7%) |
113 (9.0%) |
462 (4.2%) |
|
| Substitution |
180 (1.5%) |
9 (0.7%) |
171 (1.6%) |
|
| Unknown |
2,118 (17%) |
162 (13%) |
1,956 (18%) |
|
| Baseline HIV RNA level (log10) |
4.80 (4.11, 5.44) |
4.95 (4.34, 5.64) |
4.78 (4.07, 5.42) |
|
| Baseline CD4 count |
380 (203, 572) |
475 (324, 651) |
362 (180, 556) |
<0.001 |
Network analyses by region
Pays de la Loire
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 434/2,863, i.e. 15%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 831 distinct clusters including 25% of local clusters ( 20
400% ).
Demographics by clustering status
| Characteristic |
Overall
N = 2,863 |
Clusters size ≥3
N = 260 |
Dyads
N = 174 |
Singletons
N = 2,429 |
p-value |
| sex |
|
|
|
|
|
| Female |
965 (34%) |
27 (10%) |
47 (27%) |
891 (37%) |
|
| Male |
1,887 (66%) |
232 (89%) |
127 (73%) |
1,528 (63%) |
|
| Transgender M/F |
11 (0.4%) |
1 (0.4%) |
0 (0%) |
10 (0.4%) |
|
| Age |
51 (41, 60) |
47 (38, 56) |
46 (36, 57) |
52 (41, 60) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
55 (1.9%) |
3 (1.2%) |
4 (2.3%) |
48 (2.0%) |
|
| ≥25-<35 |
333 (12%) |
44 (17%) |
32 (18%) |
257 (11%) |
|
| ≥35-<45 |
572 (20%) |
65 (25%) |
47 (27%) |
460 (19%) |
|
| ≥45-<55 |
744 (26%) |
74 (28%) |
39 (22%) |
631 (26%) |
|
| ≥55-<80 |
1,131 (40%) |
71 (27%) |
52 (30%) |
1,008 (41%) |
|
| ≥80 |
28 (1.0%) |
3 (1.2%) |
0 (0%) |
25 (1.0%) |
|
| WHO region (origin) |
|
|
|
|
|
| WHO Africa |
829 (30%) |
15 (5.8%) |
51 (30%) |
763 (32%) |
|
| WHO Americas |
69 (2.5%) |
4 (1.5%) |
3 (1.8%) |
62 (2.6%) |
|
| WHO Eastern Mediterranean |
56 (2.0%) |
2 (0.8%) |
4 (2.4%) |
50 (2.1%) |
|
| WHO Europe |
1,821 (65%) |
237 (91%) |
111 (66%) |
1,473 (62%) |
|
| WHO South-East Asia |
11 (0.4%) |
0 (0%) |
0 (0%) |
11 (0.5%) |
|
| WHO Western Pacific |
22 (0.8%) |
2 (0.8%) |
0 (0%) |
20 (0.8%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
2,659 (93%) |
199 (77%) |
158 (91%) |
2,302 (95%) |
|
| Oui |
204 (7.1%) |
61 (23%) |
16 (9.2%) |
127 (5.2%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
128 (4.5%) |
16 (6.2%) |
8 (4.6%) |
104 (4.3%) |
|
| Blood |
60 (2.1%) |
2 (0.8%) |
2 (1.1%) |
56 (2.3%) |
|
| Heterosexual |
1,335 (47%) |
53 (20%) |
77 (44%) |
1,205 (50%) |
|
| IDU |
141 (4.9%) |
4 (1.5%) |
8 (4.6%) |
129 (5.3%) |
|
| Mother to child transmission |
53 (1.9%) |
0 (0%) |
3 (1.7%) |
50 (2.1%) |
|
| MSM |
1,039 (36%) |
182 (70%) |
69 (40%) |
788 (32%) |
|
| Others |
13 (0.5%) |
1 (0.4%) |
1 (0.6%) |
11 (0.5%) |
|
| Unknown |
94 (3.3%) |
2 (0.8%) |
6 (3.4%) |
86 (3.5%) |
|
| Drug use |
|
|
|
|
|
| Current |
236 (8.6%) |
40 (16%) |
20 (12%) |
176 (7.6%) |
|
| None |
1,875 (68%) |
160 (63%) |
103 (61%) |
1,612 (69%) |
|
| Past |
261 (9.5%) |
20 (7.8%) |
18 (11%) |
223 (9.6%) |
|
| Sometimes |
147 (5.3%) |
28 (11%) |
13 (7.6%) |
106 (4.6%) |
|
| Substitution |
26 (0.9%) |
2 (0.8%) |
2 (1.2%) |
22 (0.9%) |
|
| Unknown |
207 (7.5%) |
5 (2.0%) |
14 (8.2%) |
188 (8.1%) |
|
| Baseline HIV RNA level (log10) |
4.80 (4.09, 5.42) |
4.87 (4.39, 5.66) |
4.86 (3.96, 5.49) |
4.76 (4.07, 5.39) |
0.002 |
| Baseline CD4 count |
366 (190, 558) |
438 (317, 613) |
414 (218, 585) |
344 (173, 543) |
<0.001 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 2,429 |
Not Growing
N = 355 |
Growing
N = 79 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
891 (37%) |
70 (20%) |
4 (5.1%) |
|
| Male |
1,528 (63%) |
284 (80%) |
75 (95%) |
|
| Transgender M/F |
10 (0.4%) |
1 (0.3%) |
0 (0%) |
|
| Age |
52 (41, 60) |
44 (35, 54) |
53 (47, 61) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
48 (2.0%) |
6 (1.7%) |
1 (1.3%) |
|
| ≥25-<35 |
257 (11%) |
76 (21%) |
0 (0%) |
|
| ≥35-<45 |
460 (19%) |
99 (28%) |
13 (16%) |
|
| ≥45-<55 |
631 (26%) |
86 (24%) |
27 (34%) |
|
| ≥55-<80 |
1,008 (41%) |
87 (25%) |
36 (46%) |
|
| ≥80 |
25 (1.0%) |
1 (0.3%) |
2 (2.5%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
763 (32%) |
65 (19%) |
1 (1.3%) |
|
| WHO Americas |
62 (2.6%) |
7 (2.0%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
50 (2.1%) |
6 (1.7%) |
0 (0%) |
|
| WHO Europe |
1,473 (62%) |
271 (77%) |
77 (97%) |
|
| WHO South-East Asia |
11 (0.5%) |
0 (0%) |
0 (0%) |
|
| WHO Western Pacific |
20 (0.8%) |
1 (0.3%) |
1 (1.3%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
2,302 (95%) |
296 (83%) |
61 (77%) |
|
| Oui |
127 (5.2%) |
59 (17%) |
18 (23%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
104 (4.3%) |
19 (5.4%) |
5 (6.3%) |
|
| Blood |
56 (2.3%) |
2 (0.6%) |
2 (2.5%) |
|
| Heterosexual |
1,205 (50%) |
117 (33%) |
13 (16%) |
|
| IDU |
129 (5.3%) |
10 (2.8%) |
2 (2.5%) |
|
| Mother to child transmission |
50 (2.1%) |
3 (0.8%) |
0 (0%) |
|
| MSM |
788 (32%) |
195 (55%) |
56 (71%) |
|
| Others |
11 (0.5%) |
1 (0.3%) |
1 (1.3%) |
|
| Unknown |
86 (3.5%) |
8 (2.3%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
176 (7.6%) |
51 (15%) |
9 (12%) |
|
| None |
1,612 (69%) |
209 (60%) |
54 (69%) |
|
| Past |
223 (9.6%) |
31 (8.9%) |
7 (9.0%) |
|
| Sometimes |
106 (4.6%) |
34 (9.8%) |
7 (9.0%) |
|
| Substitution |
22 (0.9%) |
4 (1.2%) |
0 (0%) |
|
| Unknown |
188 (8.1%) |
18 (5.2%) |
1 (1.3%) |
|
| Baseline HIV RNA level (log10) |
4.76 (4.07, 5.39) |
4.86 (4.23, 5.59) |
4.95 (4.62, 5.54) |
0.003 |
| Baseline CD4 count |
344 (173, 543) |
436 (271, 614) |
432 (310, 537) |
<0.001 |
Table of cluster dispersal
| Characteristic |
local only
N = 204 |
Not clustering
N = 2,429 |
spread
N = 230 |
p-value |
| sex |
|
|
|
|
| Female |
39 (19%) |
891 (37%) |
35 (15%) |
|
| Male |
164 (80%) |
1,528 (63%) |
195 (85%) |
|
| Transgender M/F |
1 (0.5%) |
10 (0.4%) |
0 (0%) |
|
| Age |
48 (38, 57) |
52 (41, 60) |
44 (36, 55) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
3 (1.5%) |
48 (2.0%) |
4 (1.7%) |
|
| ≥25-<35 |
31 (15%) |
257 (11%) |
45 (20%) |
|
| ≥35-<45 |
42 (21%) |
460 (19%) |
70 (30%) |
|
| ≥45-<55 |
61 (30%) |
631 (26%) |
52 (23%) |
|
| ≥55-<80 |
65 (32%) |
1,008 (41%) |
58 (25%) |
|
| ≥80 |
2 (1.0%) |
25 (1.0%) |
1 (0.4%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
42 (21%) |
763 (32%) |
24 (11%) |
|
| WHO Americas |
3 (1.5%) |
62 (2.6%) |
4 (1.8%) |
|
| WHO Eastern Mediterranean |
2 (1.0%) |
50 (2.1%) |
4 (1.8%) |
|
| WHO Europe |
154 (76%) |
1,473 (62%) |
194 (86%) |
|
| WHO South-East Asia |
0 (0%) |
11 (0.5%) |
0 (0%) |
|
| WHO Western Pacific |
2 (1.0%) |
20 (0.8%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
176 (86%) |
2,302 (95%) |
181 (79%) |
|
| Oui |
28 (14%) |
127 (5.2%) |
49 (21%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
14 (6.9%) |
104 (4.3%) |
10 (4.3%) |
|
| Blood |
2 (1.0%) |
56 (2.3%) |
2 (0.9%) |
|
| Heterosexual |
76 (37%) |
1,205 (50%) |
54 (23%) |
|
| IDU |
3 (1.5%) |
129 (5.3%) |
9 (3.9%) |
|
| Mother to child transmission |
3 (1.5%) |
50 (2.1%) |
0 (0%) |
|
| MSM |
100 (49%) |
788 (32%) |
151 (66%) |
|
| Others |
1 (0.5%) |
11 (0.5%) |
1 (0.4%) |
|
| Unknown |
5 (2.5%) |
86 (3.5%) |
3 (1.3%) |
|
| Drug use |
|
|
|
|
| Current |
32 (16%) |
176 (7.6%) |
28 (12%) |
|
| None |
121 (61%) |
1,612 (69%) |
142 (63%) |
|
| Past |
14 (7.1%) |
223 (9.6%) |
24 (11%) |
|
| Sometimes |
18 (9.1%) |
106 (4.6%) |
23 (10%) |
|
| Substitution |
1 (0.5%) |
22 (0.9%) |
3 (1.3%) |
|
| Unknown |
12 (6.1%) |
188 (8.1%) |
7 (3.1%) |
|
| Baseline HIV RNA level (log10) |
4.86 (4.20, 5.49) |
4.76 (4.07, 5.39) |
4.88 (4.38, 5.78) |
0.002 |
| Baseline CD4 count |
414 (219, 618) |
344 (173, 543) |
447 (334, 586) |
<0.001 |
Occitanie
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 667/3,626, i.e. 18%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 1018 distinct clusters including 31% of local clusters ( 31
900% ).
Demographics by clustering status
| Characteristic |
Overall
N = 3,626 |
Clusters size ≥3
N = 428 |
Dyads
N = 239 |
Singletons
N = 2,959 |
p-value |
| sex |
|
|
|
|
|
| Female |
898 (25%) |
15 (3.5%) |
35 (15%) |
848 (29%) |
|
| Male |
2,712 (75%) |
410 (96%) |
201 (84%) |
2,101 (71%) |
|
| Transgender M/F |
16 (0.4%) |
3 (0.7%) |
3 (1.3%) |
10 (0.3%) |
|
| Age |
49 (39, 59) |
41 (32, 50) |
44 (36, 53) |
51 (40, 60) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
97 (2.7%) |
21 (4.9%) |
5 (2.1%) |
71 (2.4%) |
|
| ≥25-<35 |
457 (13%) |
106 (25%) |
41 (17%) |
310 (10%) |
|
| ≥35-<45 |
814 (22%) |
136 (32%) |
74 (31%) |
604 (20%) |
|
| ≥45-<55 |
968 (27%) |
99 (23%) |
72 (30%) |
797 (27%) |
|
| ≥55-<80 |
1,245 (34%) |
63 (15%) |
47 (20%) |
1,135 (38%) |
|
| ≥80 |
45 (1.2%) |
3 (0.7%) |
0 (0%) |
42 (1.4%) |
|
| WHO region (origin) |
|
|
|
|
|
| WHO Africa |
635 (19%) |
20 (4.9%) |
28 (12%) |
587 (21%) |
|
| WHO Americas |
94 (2.8%) |
9 (2.2%) |
11 (4.9%) |
74 (2.7%) |
|
| WHO Eastern Mediterranean |
106 (3.1%) |
9 (2.2%) |
8 (3.5%) |
89 (3.2%) |
|
| WHO Europe |
2,541 (74%) |
371 (91%) |
178 (79%) |
1,992 (72%) |
|
| WHO South-East Asia |
16 (0.5%) |
0 (0%) |
1 (0.4%) |
15 (0.5%) |
|
| WHO Western Pacific |
20 (0.6%) |
0 (0%) |
0 (0%) |
20 (0.7%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
3,194 (88%) |
314 (73%) |
195 (82%) |
2,685 (91%) |
|
| Oui |
432 (12%) |
114 (27%) |
44 (18%) |
274 (9.3%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
168 (4.6%) |
22 (5.1%) |
14 (5.9%) |
132 (4.5%) |
|
| Blood |
61 (1.7%) |
3 (0.7%) |
2 (0.8%) |
56 (1.9%) |
|
| Heterosexual |
1,203 (33%) |
38 (8.9%) |
58 (24%) |
1,107 (37%) |
|
| IDU |
199 (5.5%) |
7 (1.6%) |
11 (4.6%) |
181 (6.1%) |
|
| Mother to child transmission |
52 (1.4%) |
0 (0%) |
3 (1.3%) |
49 (1.7%) |
|
| MSM |
1,653 (46%) |
338 (79%) |
141 (59%) |
1,174 (40%) |
|
| Others |
29 (0.8%) |
3 (0.7%) |
2 (0.8%) |
24 (0.8%) |
|
| Unknown |
261 (7.2%) |
17 (4.0%) |
8 (3.3%) |
236 (8.0%) |
|
| Drug use |
|
|
|
|
|
| Current |
328 (11%) |
65 (17%) |
27 (13%) |
236 (9.3%) |
|
| None |
1,923 (62%) |
194 (51%) |
122 (57%) |
1,607 (64%) |
|
| Past |
351 (11%) |
36 (9.5%) |
25 (12%) |
290 (11%) |
|
| Sometimes |
296 (9.5%) |
65 (17%) |
27 (13%) |
204 (8.1%) |
|
| Substitution |
45 (1.4%) |
3 (0.8%) |
3 (1.4%) |
39 (1.5%) |
|
| Unknown |
174 (5.6%) |
14 (3.7%) |
10 (4.7%) |
150 (5.9%) |
|
| Baseline HIV RNA level (log10) |
4.92 (4.27, 5.59) |
5.07 (4.52, 5.79) |
4.91 (4.38, 5.56) |
4.88 (4.19, 5.57) |
<0.001 |
| Baseline CD4 count |
392 (202, 581) |
478 (332, 665) |
455 (319, 613) |
351 (166, 555) |
<0.001 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 2,959 |
Not Growing
N = 635 |
Growing
N = 32 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
848 (29%) |
47 (7.4%) |
3 (9.4%) |
|
| Male |
2,101 (71%) |
582 (92%) |
29 (91%) |
|
| Transgender M/F |
10 (0.3%) |
6 (0.9%) |
0 (0%) |
|
| Age |
51 (40, 60) |
42 (34, 51) |
52 (45, 58) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
71 (2.4%) |
26 (4.1%) |
0 (0%) |
|
| ≥25-<35 |
310 (10%) |
143 (23%) |
4 (13%) |
|
| ≥35-<45 |
604 (20%) |
207 (33%) |
3 (9.4%) |
|
| ≥45-<55 |
797 (27%) |
157 (25%) |
14 (44%) |
|
| ≥55-<80 |
1,135 (38%) |
100 (16%) |
10 (31%) |
|
| ≥80 |
42 (1.4%) |
2 (0.3%) |
1 (3.1%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
587 (21%) |
47 (7.8%) |
1 (3.3%) |
|
| WHO Americas |
74 (2.7%) |
20 (3.3%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
89 (3.2%) |
17 (2.8%) |
0 (0%) |
|
| WHO Europe |
1,992 (72%) |
520 (86%) |
29 (97%) |
|
| WHO South-East Asia |
15 (0.5%) |
1 (0.2%) |
0 (0%) |
|
| WHO Western Pacific |
20 (0.7%) |
0 (0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
2,685 (91%) |
483 (76%) |
26 (81%) |
|
| Oui |
274 (9.3%) |
152 (24%) |
6 (19%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
132 (4.5%) |
36 (5.7%) |
0 (0%) |
|
| Blood |
56 (1.9%) |
4 (0.6%) |
1 (3.1%) |
|
| Heterosexual |
1,107 (37%) |
92 (14%) |
4 (13%) |
|
| IDU |
181 (6.1%) |
16 (2.5%) |
2 (6.3%) |
|
| Mother to child transmission |
49 (1.7%) |
3 (0.5%) |
0 (0%) |
|
| MSM |
1,174 (40%) |
455 (72%) |
24 (75%) |
|
| Others |
24 (0.8%) |
5 (0.8%) |
0 (0%) |
|
| Unknown |
236 (8.0%) |
24 (3.8%) |
1 (3.1%) |
|
| Drug use |
|
|
|
|
| Current |
236 (9.3%) |
89 (16%) |
3 (10%) |
|
| None |
1,607 (64%) |
296 (53%) |
20 (69%) |
|
| Past |
290 (11%) |
59 (10%) |
2 (6.9%) |
|
| Sometimes |
204 (8.1%) |
89 (16%) |
3 (10%) |
|
| Substitution |
39 (1.5%) |
6 (1.1%) |
0 (0%) |
|
| Unknown |
150 (5.9%) |
23 (4.1%) |
1 (3.4%) |
|
| Baseline HIV RNA level (log10) |
4.88 (4.19, 5.57) |
5.03 (4.46, 5.69) |
5.00 (4.34, 5.43) |
<0.001 |
| Baseline CD4 count |
351 (166, 555) |
472 (331, 652) |
613 (257, 702) |
<0.001 |
Table of cluster dispersal
| Characteristic |
local only
N = 319 |
Not clustering
N = 2,959 |
spread
N = 348 |
p-value |
| sex |
|
|
|
|
| Female |
27 (8.5%) |
848 (29%) |
23 (6.6%) |
|
| Male |
287 (90%) |
2,101 (71%) |
324 (93%) |
|
| Transgender M/F |
5 (1.6%) |
10 (0.3%) |
1 (0.3%) |
|
| Age |
44 (36, 52) |
51 (40, 60) |
41 (32, 51) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
5 (1.6%) |
71 (2.4%) |
21 (6.0%) |
|
| ≥25-<35 |
60 (19%) |
310 (10%) |
87 (25%) |
|
| ≥35-<45 |
104 (33%) |
604 (20%) |
106 (30%) |
|
| ≥45-<55 |
94 (29%) |
797 (27%) |
77 (22%) |
|
| ≥55-<80 |
55 (17%) |
1,135 (38%) |
55 (16%) |
|
| ≥80 |
1 (0.3%) |
42 (1.4%) |
2 (0.6%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
33 (11%) |
587 (21%) |
15 (4.6%) |
|
| WHO Americas |
14 (4.5%) |
74 (2.7%) |
6 (1.9%) |
|
| WHO Eastern Mediterranean |
10 (3.2%) |
89 (3.2%) |
7 (2.2%) |
|
| WHO Europe |
253 (81%) |
1,992 (72%) |
296 (91%) |
|
| WHO South-East Asia |
1 (0.3%) |
15 (0.5%) |
0 (0%) |
|
| WHO Western Pacific |
0 (0%) |
20 (0.7%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
240 (75%) |
2,685 (91%) |
269 (77%) |
|
| Oui |
79 (25%) |
274 (9.3%) |
79 (23%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
19 (6.0%) |
132 (4.5%) |
17 (4.9%) |
|
| Blood |
2 (0.6%) |
56 (1.9%) |
3 (0.9%) |
|
| Heterosexual |
61 (19%) |
1,107 (37%) |
35 (10%) |
|
| IDU |
6 (1.9%) |
181 (6.1%) |
12 (3.4%) |
|
| Mother to child transmission |
1 (0.3%) |
49 (1.7%) |
2 (0.6%) |
|
| MSM |
215 (67%) |
1,174 (40%) |
264 (76%) |
|
| Others |
5 (1.6%) |
24 (0.8%) |
0 (0%) |
|
| Unknown |
10 (3.1%) |
236 (8.0%) |
15 (4.3%) |
|
| Drug use |
|
|
|
|
| Current |
44 (15%) |
236 (9.3%) |
48 (16%) |
|
| None |
168 (58%) |
1,607 (64%) |
148 (49%) |
|
| Past |
21 (7.3%) |
290 (11%) |
40 (13%) |
|
| Sometimes |
45 (16%) |
204 (8.1%) |
47 (16%) |
|
| Substitution |
3 (1.0%) |
39 (1.5%) |
3 (1.0%) |
|
| Unknown |
7 (2.4%) |
150 (5.9%) |
17 (5.6%) |
|
| Baseline HIV RNA level (log10) |
4.98 (4.44, 5.56) |
4.88 (4.19, 5.57) |
5.08 (4.52, 5.79) |
<0.001 |
| Baseline CD4 count |
465 (328, 632) |
351 (166, 555) |
477 (340, 662) |
<0.001 |
Bretagne
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 175/1,256, i.e. 14%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 508 distinct clusters including 11% of local clusters ( 5
600% ).
Demographics by clustering status
| Characteristic |
Overall
N = 1,256 |
Clusters size ≥3
N = 102 |
Dyads
N = 73 |
Singletons
N = 1,081 |
p-value |
| sex |
|
|
|
|
<0.001 |
| Female |
428 (34%) |
7 (6.9%) |
16 (22%) |
405 (37%) |
|
| Male |
822 (65%) |
94 (92%) |
57 (78%) |
671 (62%) |
|
| Transgender F/M |
1 (<0.1%) |
0 (0%) |
0 (0%) |
1 (<0.1%) |
|
| Transgender M/F |
5 (0.4%) |
1 (1.0%) |
0 (0%) |
4 (0.4%) |
|
| Age |
52 (41, 60) |
44 (36, 54) |
43 (38, 51) |
53 (43, 61) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
38 (3.0%) |
5 (4.9%) |
5 (6.8%) |
28 (2.6%) |
|
| ≥25-<35 |
129 (10%) |
18 (18%) |
9 (12%) |
102 (9.4%) |
|
| ≥35-<45 |
245 (20%) |
32 (31%) |
27 (37%) |
186 (17%) |
|
| ≥45-<55 |
310 (25%) |
24 (24%) |
19 (26%) |
267 (25%) |
|
| ≥55-<80 |
518 (41%) |
23 (23%) |
13 (18%) |
482 (45%) |
|
| ≥80 |
16 (1.3%) |
0 (0%) |
0 (0%) |
16 (1.5%) |
|
| WHO region (origin) |
|
|
|
|
|
| WHO Africa |
290 (24%) |
6 (5.9%) |
7 (9.7%) |
277 (26%) |
|
| WHO Americas |
33 (2.7%) |
1 (1.0%) |
4 (5.6%) |
28 (2.7%) |
|
| WHO Eastern Mediterranean |
9 (0.7%) |
1 (1.0%) |
0 (0%) |
8 (0.8%) |
|
| WHO Europe |
887 (72%) |
93 (92%) |
61 (85%) |
733 (69%) |
|
| WHO South-East Asia |
3 (0.2%) |
0 (0%) |
0 (0%) |
3 (0.3%) |
|
| WHO Western Pacific |
7 (0.6%) |
0 (0%) |
0 (0%) |
7 (0.7%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
1,183 (94%) |
80 (78%) |
66 (90%) |
1,037 (96%) |
|
| Oui |
73 (5.8%) |
22 (22%) |
7 (9.6%) |
44 (4.1%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
58 (4.6%) |
14 (14%) |
1 (1.4%) |
43 (4.0%) |
|
| Blood |
27 (2.1%) |
2 (2.0%) |
1 (1.4%) |
24 (2.2%) |
|
| Heterosexual |
563 (45%) |
14 (14%) |
24 (33%) |
525 (49%) |
|
| IDU |
72 (5.7%) |
4 (3.9%) |
4 (5.5%) |
64 (5.9%) |
|
| Mother to child transmission |
27 (2.1%) |
0 (0%) |
0 (0%) |
27 (2.5%) |
|
| MSM |
438 (35%) |
63 (62%) |
40 (55%) |
335 (31%) |
|
| Others |
15 (1.2%) |
1 (1.0%) |
1 (1.4%) |
13 (1.2%) |
|
| Unknown |
56 (4.5%) |
4 (3.9%) |
2 (2.7%) |
50 (4.6%) |
|
| Drug use |
|
|
|
|
|
| Current |
90 (9.0%) |
19 (23%) |
10 (16%) |
61 (7.2%) |
|
| None |
425 (43%) |
33 (40%) |
27 (42%) |
365 (43%) |
|
| Past |
74 (7.4%) |
5 (6.0%) |
7 (11%) |
62 (7.3%) |
|
| Sometimes |
23 (2.3%) |
1 (1.2%) |
3 (4.7%) |
19 (2.2%) |
|
| Substitution |
22 (2.2%) |
3 (3.6%) |
1 (1.6%) |
18 (2.1%) |
|
| Unknown |
361 (36%) |
22 (27%) |
16 (25%) |
323 (38%) |
|
| Baseline HIV RNA level (log10) |
4.87 (4.13, 5.48) |
5.12 (4.55, 6.01) |
5.00 (4.63, 5.53) |
4.80 (4.07, 5.45) |
<0.001 |
| Baseline CD4 count |
353 (180, 548) |
404 (261, 606) |
424 (274, 637) |
331 (158, 537) |
0.003 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 1,081 |
Not Growing
N = 159 |
Growing
N = 16 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
405 (37%) |
21 (13%) |
2 (13%) |
|
| Male |
671 (62%) |
137 (86%) |
14 (88%) |
|
| Transgender F/M |
1 (<0.1%) |
0 (0%) |
0 (0%) |
|
| Transgender M/F |
4 (0.4%) |
1 (0.6%) |
0 (0%) |
|
| Age |
53 (43, 61) |
43 (35, 53) |
46 (39, 51) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
28 (2.6%) |
10 (6.3%) |
0 (0%) |
|
| ≥25-<35 |
102 (9.4%) |
27 (17%) |
0 (0%) |
|
| ≥35-<45 |
186 (17%) |
52 (33%) |
7 (44%) |
|
| ≥45-<55 |
267 (25%) |
37 (23%) |
6 (38%) |
|
| ≥55-<80 |
482 (45%) |
33 (21%) |
3 (19%) |
|
| ≥80 |
16 (1.5%) |
0 (0%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
277 (26%) |
13 (8.3%) |
0 (0%) |
|
| WHO Americas |
28 (2.7%) |
5 (3.2%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
8 (0.8%) |
1 (0.6%) |
0 (0%) |
|
| WHO Europe |
733 (69%) |
138 (88%) |
16 (100%) |
|
| WHO South-East Asia |
3 (0.3%) |
0 (0%) |
0 (0%) |
|
| WHO Western Pacific |
7 (0.7%) |
0 (0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
1,037 (96%) |
132 (83%) |
14 (88%) |
|
| Oui |
44 (4.1%) |
27 (17%) |
2 (13%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
43 (4.0%) |
11 (6.9%) |
4 (25%) |
|
| Blood |
24 (2.2%) |
3 (1.9%) |
0 (0%) |
|
| Heterosexual |
525 (49%) |
35 (22%) |
3 (19%) |
|
| IDU |
64 (5.9%) |
6 (3.8%) |
2 (13%) |
|
| Mother to child transmission |
27 (2.5%) |
0 (0%) |
0 (0%) |
|
| MSM |
335 (31%) |
96 (60%) |
7 (44%) |
|
| Others |
13 (1.2%) |
2 (1.3%) |
0 (0%) |
|
| Unknown |
50 (4.6%) |
6 (3.8%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
61 (7.2%) |
25 (19%) |
4 (29%) |
|
| None |
365 (43%) |
56 (42%) |
4 (29%) |
|
| Past |
62 (7.3%) |
9 (6.8%) |
3 (21%) |
|
| Sometimes |
19 (2.2%) |
4 (3.0%) |
0 (0%) |
|
| Substitution |
18 (2.1%) |
3 (2.3%) |
1 (7.1%) |
|
| Unknown |
323 (38%) |
36 (27%) |
2 (14%) |
|
| Baseline HIV RNA level (log10) |
4.80 (4.07, 5.45) |
5.08 (4.59, 5.80) |
5.45 (4.26, 5.63) |
<0.001 |
| Baseline CD4 count |
331 (158, 537) |
416 (259, 589) |
796 (294, 899) |
<0.001 |
Table of cluster dispersal
| Characteristic |
local only
N = 56 |
Not clustering
N = 1,081 |
spread
N = 119 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
12 (21%) |
405 (37%) |
11 (9.2%) |
|
| Male |
44 (79%) |
671 (62%) |
107 (90%) |
|
| Transgender F/M |
0 (0%) |
1 (<0.1%) |
0 (0%) |
|
| Transgender M/F |
0 (0%) |
4 (0.4%) |
1 (0.8%) |
|
| Age |
43 (37, 51) |
53 (43, 61) |
44 (36, 54) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
2 (3.6%) |
28 (2.6%) |
8 (6.7%) |
|
| ≥25-<35 |
9 (16%) |
102 (9.4%) |
18 (15%) |
|
| ≥35-<45 |
21 (38%) |
186 (17%) |
38 (32%) |
|
| ≥45-<55 |
15 (27%) |
267 (25%) |
28 (24%) |
|
| ≥55-<80 |
9 (16%) |
482 (45%) |
27 (23%) |
|
| ≥80 |
0 (0%) |
16 (1.5%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
5 (9.1%) |
277 (26%) |
8 (6.8%) |
|
| WHO Americas |
3 (5.5%) |
28 (2.7%) |
2 (1.7%) |
|
| WHO Eastern Mediterranean |
0 (0%) |
8 (0.8%) |
1 (0.8%) |
|
| WHO Europe |
47 (85%) |
733 (69%) |
107 (91%) |
|
| WHO South-East Asia |
0 (0%) |
3 (0.3%) |
0 (0%) |
|
| WHO Western Pacific |
0 (0%) |
7 (0.7%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
51 (91%) |
1,037 (96%) |
95 (80%) |
|
| Oui |
5 (8.9%) |
44 (4.1%) |
24 (20%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
1 (1.8%) |
43 (4.0%) |
14 (12%) |
|
| Blood |
2 (3.6%) |
24 (2.2%) |
1 (0.8%) |
|
| Heterosexual |
17 (30%) |
525 (49%) |
21 (18%) |
|
| IDU |
5 (8.9%) |
64 (5.9%) |
3 (2.5%) |
|
| Mother to child transmission |
0 (0%) |
27 (2.5%) |
0 (0%) |
|
| MSM |
28 (50%) |
335 (31%) |
75 (63%) |
|
| Others |
1 (1.8%) |
13 (1.2%) |
1 (0.8%) |
|
| Unknown |
2 (3.6%) |
50 (4.6%) |
4 (3.4%) |
|
| Drug use |
|
|
|
|
| Current |
12 (24%) |
61 (7.2%) |
17 (18%) |
|
| None |
20 (39%) |
365 (43%) |
40 (42%) |
|
| Past |
5 (9.8%) |
62 (7.3%) |
7 (7.3%) |
|
| Sometimes |
2 (3.9%) |
19 (2.2%) |
2 (2.1%) |
|
| Substitution |
2 (3.9%) |
18 (2.1%) |
2 (2.1%) |
|
| Unknown |
10 (20%) |
323 (38%) |
28 (29%) |
|
| Baseline HIV RNA level (log10) |
4.98 (4.55, 5.40) |
4.80 (4.07, 5.45) |
5.15 (4.64, 5.94) |
<0.001 |
| Baseline CD4 count |
446 (259, 665) |
331 (158, 537) |
415 (273, 590) |
0.003 |
Provence-Alpes-Côte-d’Azur
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 519/2,787, i.e. 19%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 844 distinct clusters including 39% of local clusters ( 32
800% ).
Demographics by clustering status
| Characteristic |
Overall
N = 2,787 |
Clusters size ≥3
N = 302 |
Dyads
N = 217 |
Singletons
N = 2,268 |
p-value |
| sex |
|
|
|
|
|
| Female |
728 (26%) |
21 (7.0%) |
38 (18%) |
669 (29%) |
|
| Male |
2,005 (72%) |
277 (92%) |
175 (81%) |
1,553 (68%) |
|
| Transgender M/F |
54 (1.9%) |
4 (1.3%) |
4 (1.8%) |
46 (2.0%) |
|
| Age |
52 (41, 60) |
42 (34, 54) |
45 (35, 55) |
54 (43, 60) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
59 (2.1%) |
18 (6.0%) |
12 (5.5%) |
29 (1.3%) |
|
| ≥25-<35 |
307 (11%) |
62 (21%) |
41 (19%) |
204 (9.0%) |
|
| ≥35-<45 |
545 (20%) |
90 (30%) |
53 (24%) |
402 (18%) |
|
| ≥45-<55 |
671 (24%) |
61 (20%) |
54 (25%) |
556 (25%) |
|
| ≥55-<80 |
1,179 (42%) |
70 (23%) |
56 (26%) |
1,053 (46%) |
|
| ≥80 |
26 (0.9%) |
1 (0.3%) |
1 (0.5%) |
24 (1.1%) |
|
| WHO region (origin) |
|
|
|
|
|
| WHO Africa |
308 (16%) |
11 (4.7%) |
27 (18%) |
270 (18%) |
|
| WHO Americas |
118 (6.1%) |
8 (3.4%) |
6 (3.9%) |
104 (6.8%) |
|
| WHO Eastern Mediterranean |
89 (4.6%) |
6 (2.6%) |
8 (5.2%) |
75 (4.9%) |
|
| WHO Europe |
1,382 (72%) |
209 (89%) |
110 (71%) |
1,063 (69%) |
|
| WHO South-East Asia |
7 (0.4%) |
1 (0.4%) |
0 (0%) |
6 (0.4%) |
|
| WHO Western Pacific |
18 (0.9%) |
0 (0%) |
3 (1.9%) |
15 (1.0%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
2,555 (92%) |
242 (80%) |
195 (90%) |
2,118 (93%) |
|
| Oui |
232 (8.3%) |
60 (20%) |
22 (10%) |
150 (6.6%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
123 (4.4%) |
19 (6.3%) |
9 (4.1%) |
95 (4.2%) |
|
| Blood |
44 (1.6%) |
2 (0.7%) |
2 (0.9%) |
40 (1.8%) |
|
| Heterosexual |
992 (36%) |
52 (17%) |
54 (25%) |
886 (39%) |
|
| IDU |
392 (14%) |
18 (6.0%) |
15 (6.9%) |
359 (16%) |
|
| Mother to child transmission |
51 (1.8%) |
0 (0%) |
5 (2.3%) |
46 (2.0%) |
|
| MSM |
1,109 (40%) |
209 (69%) |
125 (58%) |
775 (34%) |
|
| Others |
11 (0.4%) |
0 (0%) |
1 (0.5%) |
10 (0.4%) |
|
| Unknown |
65 (2.3%) |
2 (0.7%) |
6 (2.8%) |
57 (2.5%) |
|
| Drug use |
|
|
|
|
|
| Current |
300 (11%) |
56 (19%) |
32 (15%) |
212 (9.5%) |
|
| None |
788 (29%) |
77 (26%) |
68 (33%) |
643 (29%) |
|
| Past |
335 (12%) |
46 (16%) |
22 (11%) |
267 (12%) |
|
| Sometimes |
33 (1.2%) |
5 (1.7%) |
2 (1.0%) |
26 (1.2%) |
|
| Substitution |
55 (2.0%) |
0 (0%) |
3 (1.4%) |
52 (2.3%) |
|
| Unknown |
1,215 (45%) |
111 (38%) |
80 (39%) |
1,024 (46%) |
|
| Baseline HIV RNA level (log10) |
4.81 (4.08, 5.46) |
4.93 (4.24, 5.54) |
4.82 (4.07, 5.30) |
4.79 (4.00, 5.47) |
0.074 |
| Baseline CD4 count |
410 (247, 592) |
504 (352, 688) |
480 (330, 625) |
368 (205, 556) |
<0.001 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 2,268 |
Not Growing
N = 505 |
Growing
N = 14 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
669 (29%) |
56 (11%) |
3 (21%) |
|
| Male |
1,553 (68%) |
442 (88%) |
10 (71%) |
|
| Transgender M/F |
46 (2.0%) |
7 (1.4%) |
1 (7.1%) |
|
| Age |
54 (43, 60) |
43 (34, 53) |
60 (56, 65) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
29 (1.3%) |
30 (5.9%) |
0 (0%) |
|
| ≥25-<35 |
204 (9.0%) |
103 (20%) |
0 (0%) |
|
| ≥35-<45 |
402 (18%) |
143 (28%) |
0 (0%) |
|
| ≥45-<55 |
556 (25%) |
114 (23%) |
1 (7.1%) |
|
| ≥55-<80 |
1,053 (46%) |
113 (22%) |
13 (93%) |
|
| ≥80 |
24 (1.1%) |
2 (0.4%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
270 (18%) |
38 (10%) |
0 (0%) |
|
| WHO Americas |
104 (6.8%) |
14 (3.7%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
75 (4.9%) |
14 (3.7%) |
0 (0%) |
|
| WHO Europe |
1,063 (69%) |
309 (82%) |
10 (100%) |
|
| WHO South-East Asia |
6 (0.4%) |
1 (0.3%) |
0 (0%) |
|
| WHO Western Pacific |
15 (1.0%) |
3 (0.8%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
2,118 (93%) |
423 (84%) |
14 (100%) |
|
| Oui |
150 (6.6%) |
82 (16%) |
0 (0%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
95 (4.2%) |
26 (5.1%) |
2 (14%) |
|
| Blood |
40 (1.8%) |
3 (0.6%) |
1 (7.1%) |
|
| Heterosexual |
886 (39%) |
104 (21%) |
2 (14%) |
|
| IDU |
359 (16%) |
26 (5.1%) |
7 (50%) |
|
| Mother to child transmission |
46 (2.0%) |
5 (1.0%) |
0 (0%) |
|
| MSM |
775 (34%) |
332 (66%) |
2 (14%) |
|
| Others |
10 (0.4%) |
1 (0.2%) |
0 (0%) |
|
| Unknown |
57 (2.5%) |
8 (1.6%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
212 (9.5%) |
87 (18%) |
1 (7.1%) |
|
| None |
643 (29%) |
142 (29%) |
3 (21%) |
|
| Past |
267 (12%) |
64 (13%) |
4 (29%) |
|
| Sometimes |
26 (1.2%) |
7 (1.4%) |
0 (0%) |
|
| Substitution |
52 (2.3%) |
3 (0.6%) |
0 (0%) |
|
| Unknown |
1,024 (46%) |
185 (38%) |
6 (43%) |
|
| Baseline HIV RNA level (log10) |
4.79 (4.00, 5.47) |
4.86 (4.18, 5.43) |
5.04 (4.89, 5.08) |
0.2 |
| Baseline CD4 count |
368 (205, 556) |
484 (345, 659) |
238 (221, 240) |
<0.001 |
Table of cluster dispersal
| Characteristic |
local only
N = 328 |
Not clustering
N = 2,268 |
spread
N = 191 |
p-value |
| sex |
|
|
|
|
| Female |
38 (12%) |
669 (29%) |
21 (11%) |
|
| Male |
287 (88%) |
1,553 (68%) |
165 (86%) |
|
| Transgender M/F |
3 (0.9%) |
46 (2.0%) |
5 (2.6%) |
|
| Age |
44 (35, 55) |
54 (43, 60) |
41 (32, 53) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
17 (5.2%) |
29 (1.3%) |
13 (6.8%) |
|
| ≥25-<35 |
55 (17%) |
204 (9.0%) |
48 (25%) |
|
| ≥35-<45 |
93 (28%) |
402 (18%) |
50 (26%) |
|
| ≥45-<55 |
76 (23%) |
556 (25%) |
39 (20%) |
|
| ≥55-<80 |
85 (26%) |
1,053 (46%) |
41 (21%) |
|
| ≥80 |
2 (0.6%) |
24 (1.1%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
|
| WHO Africa |
30 (13%) |
270 (18%) |
8 (5.3%) |
|
| WHO Americas |
10 (4.2%) |
104 (6.8%) |
4 (2.7%) |
|
| WHO Eastern Mediterranean |
13 (5.4%) |
75 (4.9%) |
1 (0.7%) |
|
| WHO Europe |
183 (77%) |
1,063 (69%) |
136 (91%) |
|
| WHO South-East Asia |
0 (0%) |
6 (0.4%) |
1 (0.7%) |
|
| WHO Western Pacific |
3 (1.3%) |
15 (1.0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
274 (84%) |
2,118 (93%) |
163 (85%) |
|
| Oui |
54 (16%) |
150 (6.6%) |
28 (15%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
18 (5.5%) |
95 (4.2%) |
10 (5.2%) |
|
| Blood |
1 (0.3%) |
40 (1.8%) |
3 (1.6%) |
|
| Heterosexual |
75 (23%) |
886 (39%) |
31 (16%) |
|
| IDU |
16 (4.9%) |
359 (16%) |
17 (8.9%) |
|
| Mother to child transmission |
3 (0.9%) |
46 (2.0%) |
2 (1.0%) |
|
| MSM |
207 (63%) |
775 (34%) |
127 (66%) |
|
| Others |
1 (0.3%) |
10 (0.4%) |
0 (0%) |
|
| Unknown |
7 (2.1%) |
57 (2.5%) |
1 (0.5%) |
|
| Drug use |
|
|
|
|
| Current |
51 (16%) |
212 (9.5%) |
37 (20%) |
|
| None |
95 (30%) |
643 (29%) |
50 (27%) |
|
| Past |
39 (12%) |
267 (12%) |
29 (16%) |
|
| Sometimes |
3 (0.9%) |
26 (1.2%) |
4 (2.2%) |
|
| Substitution |
2 (0.6%) |
52 (2.3%) |
1 (0.5%) |
|
| Unknown |
126 (40%) |
1,024 (46%) |
65 (35%) |
|
| Baseline HIV RNA level (log10) |
4.76 (4.04, 5.30) |
4.79 (4.00, 5.47) |
4.99 (4.51, 5.64) |
0.005 |
| Baseline CD4 count |
484 (342, 644) |
368 (205, 556) |
481 (325, 682) |
<0.001 |
Normandie
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 102/690, i.e. 15%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 395 distinct clusters including 13% of local clusters ( 5
300% ).
Demographics by clustering status
| Characteristic |
Overall
N = 690 |
Clusters size ≥3
N = 53 |
Dyads
N = 49 |
Singletons
N = 588 |
p-value |
| sex |
|
|
|
|
<0.001 |
| Female |
242 (35%) |
5 (9.4%) |
8 (16%) |
229 (39%) |
|
| Male |
431 (62%) |
48 (91%) |
39 (80%) |
344 (59%) |
|
| Transgender F/M |
1 (0.1%) |
0 (0%) |
0 (0%) |
1 (0.2%) |
|
| Transgender M/F |
16 (2.3%) |
0 (0%) |
2 (4.1%) |
14 (2.4%) |
|
| Age |
49 (38, 58) |
47 (35, 53) |
40 (33, 52) |
50 (39, 59) |
0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
21 (3.0%) |
4 (7.5%) |
2 (4.1%) |
15 (2.6%) |
|
| ≥25-<35 |
107 (16%) |
9 (17%) |
13 (27%) |
85 (14%) |
|
| ≥35-<45 |
148 (21%) |
10 (19%) |
15 (31%) |
123 (21%) |
|
| ≥45-<55 |
174 (25%) |
20 (38%) |
10 (20%) |
144 (24%) |
|
| ≥55-<80 |
233 (34%) |
10 (19%) |
9 (18%) |
214 (36%) |
|
| ≥80 |
7 (1.0%) |
0 (0%) |
0 (0%) |
7 (1.2%) |
|
| WHO region (origin) |
|
|
|
|
<0.001 |
| WHO Africa |
206 (31%) |
5 (9.8%) |
4 (8.2%) |
197 (35%) |
|
| WHO Americas |
36 (5.4%) |
2 (3.9%) |
5 (10%) |
29 (5.1%) |
|
| WHO Eastern Mediterranean |
6 (0.9%) |
0 (0%) |
1 (2.0%) |
5 (0.9%) |
|
| WHO Europe |
419 (62%) |
44 (86%) |
39 (80%) |
336 (59%) |
|
| WHO South-East Asia |
3 (0.4%) |
0 (0%) |
0 (0%) |
3 (0.5%) |
|
| WHO Western Pacific |
1 (0.1%) |
0 (0%) |
0 (0%) |
1 (0.2%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
578 (84%) |
35 (66%) |
36 (73%) |
507 (86%) |
|
| Oui |
112 (16%) |
18 (34%) |
13 (27%) |
81 (14%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
45 (6.5%) |
6 (11%) |
7 (14%) |
32 (5.4%) |
|
| Blood |
11 (1.6%) |
0 (0%) |
1 (2.0%) |
10 (1.7%) |
|
| Heterosexual |
356 (52%) |
18 (34%) |
13 (27%) |
325 (55%) |
|
| IDU |
39 (5.7%) |
2 (3.8%) |
1 (2.0%) |
36 (6.1%) |
|
| Mother to child transmission |
8 (1.2%) |
0 (0%) |
0 (0%) |
8 (1.4%) |
|
| MSM |
203 (29%) |
26 (49%) |
26 (53%) |
151 (26%) |
|
| Others |
6 (0.9%) |
0 (0%) |
0 (0%) |
6 (1.0%) |
|
| Unknown |
22 (3.2%) |
1 (1.9%) |
1 (2.0%) |
20 (3.4%) |
|
| Drug use |
|
|
|
|
|
| Current |
51 (11%) |
7 (16%) |
7 (18%) |
37 (9.4%) |
|
| None |
309 (65%) |
25 (56%) |
23 (58%) |
261 (66%) |
|
| Past |
47 (9.8%) |
10 (22%) |
4 (10%) |
33 (8.4%) |
|
| Sometimes |
18 (3.8%) |
1 (2.2%) |
3 (7.5%) |
14 (3.6%) |
|
| Substitution |
21 (4.4%) |
1 (2.2%) |
0 (0%) |
20 (5.1%) |
|
| Unknown |
33 (6.9%) |
1 (2.2%) |
3 (7.5%) |
29 (7.4%) |
|
| Baseline HIV RNA level (log10) |
4.78 (3.87, 5.53) |
5.32 (4.40, 6.28) |
4.91 (4.25, 5.46) |
4.75 (3.80, 5.50) |
0.017 |
| Baseline CD4 count |
353 (180, 575) |
477 (306, 631) |
415 (254, 582) |
326 (149, 561) |
0.004 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 588 |
Not Growing
N = 100 |
Growing
N = 2 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
229 (39%) |
13 (13%) |
0 (0%) |
|
| Male |
344 (59%) |
85 (85%) |
2 (100%) |
|
| Transgender F/M |
1 (0.2%) |
0 (0%) |
0 (0%) |
|
| Transgender M/F |
14 (2.4%) |
2 (2.0%) |
0 (0%) |
|
| Age |
50 (39, 59) |
43 (33, 53) |
56 (46, 65) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
15 (2.6%) |
6 (6.0%) |
0 (0%) |
|
| ≥25-<35 |
85 (14%) |
22 (22%) |
0 (0%) |
|
| ≥35-<45 |
123 (21%) |
25 (25%) |
0 (0%) |
|
| ≥45-<55 |
144 (24%) |
29 (29%) |
1 (50%) |
|
| ≥55-<80 |
214 (36%) |
18 (18%) |
1 (50%) |
|
| ≥80 |
7 (1.2%) |
0 (0%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
<0.001 |
| WHO Africa |
197 (35%) |
9 (9.2%) |
0 (0%) |
|
| WHO Americas |
29 (5.1%) |
7 (7.1%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
5 (0.9%) |
1 (1.0%) |
0 (0%) |
|
| WHO Europe |
336 (59%) |
81 (83%) |
2 (100%) |
|
| WHO South-East Asia |
3 (0.5%) |
0 (0%) |
0 (0%) |
|
| WHO Western Pacific |
1 (0.2%) |
0 (0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
507 (86%) |
69 (69%) |
2 (100%) |
|
| Oui |
81 (14%) |
31 (31%) |
0 (0%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
32 (5.4%) |
13 (13%) |
0 (0%) |
|
| Blood |
10 (1.7%) |
1 (1.0%) |
0 (0%) |
|
| Heterosexual |
325 (55%) |
31 (31%) |
0 (0%) |
|
| IDU |
36 (6.1%) |
2 (2.0%) |
1 (50%) |
|
| Mother to child transmission |
8 (1.4%) |
0 (0%) |
0 (0%) |
|
| MSM |
151 (26%) |
51 (51%) |
1 (50%) |
|
| Others |
6 (1.0%) |
0 (0%) |
0 (0%) |
|
| Unknown |
20 (3.4%) |
2 (2.0%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
37 (9.4%) |
13 (16%) |
1 (50%) |
|
| None |
261 (66%) |
48 (58%) |
0 (0%) |
|
| Past |
33 (8.4%) |
14 (17%) |
0 (0%) |
|
| Sometimes |
14 (3.6%) |
4 (4.8%) |
0 (0%) |
|
| Substitution |
20 (5.1%) |
0 (0%) |
1 (50%) |
|
| Unknown |
29 (7.4%) |
4 (4.8%) |
0 (0%) |
|
| Baseline HIV RNA level (log10) |
4.75 (3.80, 5.50) |
5.07 (4.30, 5.79) |
NA (NA, NA) |
0.012 |
| Baseline CD4 count |
326 (149, 561) |
474 (291, 601) |
NA (NA, NA) |
0.001 |
Table of cluster dispersal
| Characteristic |
local only
N = 53 |
Not clustering
N = 588 |
spread
N = 49 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
5 (9.4%) |
229 (39%) |
8 (16%) |
|
| Male |
48 (91%) |
344 (59%) |
39 (80%) |
|
| Transgender F/M |
0 (0%) |
1 (0.2%) |
0 (0%) |
|
| Transgender M/F |
0 (0%) |
14 (2.4%) |
2 (4.1%) |
|
| Age |
41 (32, 53) |
50 (39, 59) |
46 (34, 54) |
0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
6 (11%) |
15 (2.6%) |
0 (0%) |
|
| ≥25-<35 |
9 (17%) |
85 (14%) |
13 (27%) |
|
| ≥35-<45 |
15 (28%) |
123 (21%) |
10 (20%) |
|
| ≥45-<55 |
14 (26%) |
144 (24%) |
16 (33%) |
|
| ≥55-<80 |
9 (17%) |
214 (36%) |
10 (20%) |
|
| ≥80 |
0 (0%) |
7 (1.2%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
<0.001 |
| WHO Africa |
4 (7.7%) |
197 (35%) |
5 (10%) |
|
| WHO Americas |
1 (1.9%) |
29 (5.1%) |
6 (13%) |
|
| WHO Eastern Mediterranean |
0 (0%) |
5 (0.9%) |
1 (2.1%) |
|
| WHO Europe |
47 (90%) |
336 (59%) |
36 (75%) |
|
| WHO South-East Asia |
0 (0%) |
3 (0.5%) |
0 (0%) |
|
| WHO Western Pacific |
0 (0%) |
1 (0.2%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
33 (62%) |
507 (86%) |
38 (78%) |
|
| Oui |
20 (38%) |
81 (14%) |
11 (22%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
9 (17%) |
32 (5.4%) |
4 (8.2%) |
|
| Blood |
0 (0%) |
10 (1.7%) |
1 (2.0%) |
|
| Heterosexual |
13 (25%) |
325 (55%) |
18 (37%) |
|
| IDU |
1 (1.9%) |
36 (6.1%) |
2 (4.1%) |
|
| Mother to child transmission |
0 (0%) |
8 (1.4%) |
0 (0%) |
|
| MSM |
28 (53%) |
151 (26%) |
24 (49%) |
|
| Others |
0 (0%) |
6 (1.0%) |
0 (0%) |
|
| Unknown |
2 (3.8%) |
20 (3.4%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
8 (19%) |
37 (9.4%) |
6 (14%) |
|
| None |
25 (58%) |
261 (66%) |
23 (55%) |
|
| Past |
7 (16%) |
33 (8.4%) |
7 (17%) |
|
| Sometimes |
2 (4.7%) |
14 (3.6%) |
2 (4.8%) |
|
| Substitution |
0 (0%) |
20 (5.1%) |
1 (2.4%) |
|
| Unknown |
1 (2.3%) |
29 (7.4%) |
3 (7.1%) |
|
| Baseline HIV RNA level (log10) |
5.00 (4.28, 5.46) |
4.75 (3.80, 5.50) |
5.33 (4.36, 5.85) |
0.034 |
| Baseline CD4 count |
476 (319, 607) |
326 (149, 561) |
435 (245, 572) |
0.004 |
Guadeloupe
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 91/645, i.e. 14%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 186 distinct clusters including 30% of local clusters ( 5
600% ).
Demographics by clustering status
| Characteristic |
Overall
N = 645 |
Clusters size ≥3
N = 47 |
Dyads
N = 44 |
Singletons
N = 554 |
p-value |
| sex |
|
|
|
|
<0.001 |
| Female |
240 (37%) |
2 (4.3%) |
14 (32%) |
224 (40%) |
|
| Male |
405 (63%) |
45 (96%) |
30 (68%) |
330 (60%) |
|
| Age |
50 (38, 60) |
34 (27, 47) |
40 (33, 53) |
51 (41, 60) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
29 (4.5%) |
6 (13%) |
3 (6.8%) |
20 (3.6%) |
|
| ≥25-<35 |
100 (16%) |
19 (40%) |
10 (23%) |
71 (13%) |
|
| ≥35-<45 |
110 (17%) |
7 (15%) |
13 (30%) |
90 (16%) |
|
| ≥45-<55 |
169 (26%) |
10 (21%) |
9 (20%) |
150 (27%) |
|
| ≥55-<80 |
223 (35%) |
5 (11%) |
9 (20%) |
209 (38%) |
|
| ≥80 |
14 (2.2%) |
0 (0%) |
0 (0%) |
14 (2.5%) |
|
| WHO region (origin) |
|
|
|
|
<0.001 |
| WHO Africa |
4 (0.6%) |
0 (0%) |
0 (0%) |
4 (0.7%) |
|
| WHO Americas |
232 (36%) |
4 (8.5%) |
7 (16%) |
221 (40%) |
|
| WHO Eastern Mediterranean |
2 (0.3%) |
0 (0%) |
0 (0%) |
2 (0.4%) |
|
| WHO Europe |
399 (62%) |
43 (91%) |
37 (84%) |
319 (58%) |
|
| WHO South-East Asia |
1 (0.2%) |
0 (0%) |
0 (0%) |
1 (0.2%) |
|
| WHO Western Pacific |
1 (0.2%) |
0 (0%) |
0 (0%) |
1 (0.2%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
616 (96%) |
38 (81%) |
42 (95%) |
536 (97%) |
|
| Oui |
29 (4.5%) |
9 (19%) |
2 (4.5%) |
18 (3.2%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
41 (6.4%) |
7 (15%) |
5 (11%) |
29 (5.2%) |
|
| Blood |
5 (0.8%) |
0 (0%) |
0 (0%) |
5 (0.9%) |
|
| Heterosexual |
470 (73%) |
17 (36%) |
27 (61%) |
426 (77%) |
|
| IDU |
7 (1.1%) |
0 (0%) |
0 (0%) |
7 (1.3%) |
|
| Mother to child transmission |
6 (0.9%) |
0 (0%) |
0 (0%) |
6 (1.1%) |
|
| MSM |
101 (16%) |
22 (47%) |
12 (27%) |
67 (12%) |
|
| Others |
1 (0.2%) |
0 (0%) |
0 (0%) |
1 (0.2%) |
|
| Unknown |
14 (2.2%) |
1 (2.1%) |
0 (0%) |
13 (2.3%) |
|
| Drug use |
|
|
|
|
|
| Current |
44 (7.8%) |
7 (17%) |
5 (14%) |
32 (6.6%) |
|
| None |
425 (75%) |
30 (71%) |
27 (75%) |
368 (76%) |
|
| Past |
45 (8.0%) |
0 (0%) |
1 (2.8%) |
44 (9.0%) |
|
| Sometimes |
17 (3.0%) |
3 (7.1%) |
2 (5.6%) |
12 (2.5%) |
|
| Substitution |
2 (0.4%) |
0 (0%) |
0 (0%) |
2 (0.4%) |
|
| Unknown |
32 (5.7%) |
2 (4.8%) |
1 (2.8%) |
29 (6.0%) |
|
| Baseline HIV RNA level (log10) |
4.67 (4.07, 5.16) |
4.73 (4.05, 4.95) |
4.69 (4.28, 5.32) |
4.67 (4.06, 5.16) |
0.7 |
| Baseline CD4 count |
332 (148, 495) |
406 (295, 575) |
413 (274, 515) |
323 (132, 486) |
0.013 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 554 |
Not Growing
N = 90 |
Growing
N = 1 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
224 (40%) |
16 (18%) |
0 (0%) |
|
| Male |
330 (60%) |
74 (82%) |
1 (100%) |
|
| Age |
51 (41, 60) |
37 (29, 48) |
60 (60, 60) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
20 (3.6%) |
9 (10%) |
0 (0%) |
|
| ≥25-<35 |
71 (13%) |
29 (32%) |
0 (0%) |
|
| ≥35-<45 |
90 (16%) |
20 (22%) |
0 (0%) |
|
| ≥45-<55 |
150 (27%) |
19 (21%) |
0 (0%) |
|
| ≥55-<80 |
209 (38%) |
13 (14%) |
1 (100%) |
|
| ≥80 |
14 (2.5%) |
0 (0%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
<0.001 |
| WHO Africa |
4 (0.7%) |
0 (0%) |
0 (0%) |
|
| WHO Americas |
221 (40%) |
11 (12%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
2 (0.4%) |
0 (0%) |
0 (0%) |
|
| WHO Europe |
319 (58%) |
79 (88%) |
1 (100%) |
|
| WHO South-East Asia |
1 (0.2%) |
0 (0%) |
0 (0%) |
|
| WHO Western Pacific |
1 (0.2%) |
0 (0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
0.002 |
| Non |
536 (97%) |
79 (88%) |
1 (100%) |
|
| Oui |
18 (3.2%) |
11 (12%) |
0 (0%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
29 (5.2%) |
12 (13%) |
0 (0%) |
|
| Blood |
5 (0.9%) |
0 (0%) |
0 (0%) |
|
| Heterosexual |
426 (77%) |
44 (49%) |
0 (0%) |
|
| IDU |
7 (1.3%) |
0 (0%) |
0 (0%) |
|
| Mother to child transmission |
6 (1.1%) |
0 (0%) |
0 (0%) |
|
| MSM |
67 (12%) |
33 (37%) |
1 (100%) |
|
| Others |
1 (0.2%) |
0 (0%) |
0 (0%) |
|
| Unknown |
13 (2.3%) |
1 (1.1%) |
0 (0%) |
|
| Drug use |
|
|
|
0.015 |
| Current |
32 (6.6%) |
12 (16%) |
0 (0%) |
|
| None |
368 (76%) |
56 (73%) |
1 (100%) |
|
| Past |
44 (9.0%) |
1 (1.3%) |
0 (0%) |
|
| Sometimes |
12 (2.5%) |
5 (6.5%) |
0 (0%) |
|
| Substitution |
2 (0.4%) |
0 (0%) |
0 (0%) |
|
| Unknown |
29 (6.0%) |
3 (3.9%) |
0 (0%) |
|
| Baseline HIV RNA level (log10) |
4.67 (4.06, 5.16) |
4.71 (4.25, 5.18) |
NA (NA, NA) |
0.7 |
| Baseline CD4 count |
323 (132, 486) |
408 (290, 549) |
NA (NA, NA) |
0.005 |
Table of cluster dispersal
| Characteristic |
local only
N = 56 |
Not clustering
N = 554 |
spread
N = 35 |
p-value |
| sex |
|
|
|
<0.001 |
| Female |
12 (21%) |
224 (40%) |
4 (11%) |
|
| Male |
44 (79%) |
330 (60%) |
31 (89%) |
|
| Age |
39 (31, 50) |
51 (41, 60) |
35 (27, 46) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
6 (11%) |
20 (3.6%) |
3 (8.6%) |
|
| ≥25-<35 |
15 (27%) |
71 (13%) |
14 (40%) |
|
| ≥35-<45 |
11 (20%) |
90 (16%) |
9 (26%) |
|
| ≥45-<55 |
15 (27%) |
150 (27%) |
4 (11%) |
|
| ≥55-<80 |
9 (16%) |
209 (38%) |
5 (14%) |
|
| ≥80 |
0 (0%) |
14 (2.5%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
<0.001 |
| WHO Africa |
0 (0%) |
4 (0.7%) |
0 (0%) |
|
| WHO Americas |
7 (13%) |
221 (40%) |
4 (11%) |
|
| WHO Eastern Mediterranean |
0 (0%) |
2 (0.4%) |
0 (0%) |
|
| WHO Europe |
49 (88%) |
319 (58%) |
31 (89%) |
|
| WHO South-East Asia |
0 (0%) |
1 (0.2%) |
0 (0%) |
|
| WHO Western Pacific |
0 (0%) |
1 (0.2%) |
0 (0%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
53 (95%) |
536 (97%) |
27 (77%) |
|
| Oui |
3 (5.4%) |
18 (3.2%) |
8 (23%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
7 (13%) |
29 (5.2%) |
5 (14%) |
|
| Blood |
0 (0%) |
5 (0.9%) |
0 (0%) |
|
| Heterosexual |
32 (57%) |
426 (77%) |
12 (34%) |
|
| IDU |
0 (0%) |
7 (1.3%) |
0 (0%) |
|
| Mother to child transmission |
0 (0%) |
6 (1.1%) |
0 (0%) |
|
| MSM |
17 (30%) |
67 (12%) |
17 (49%) |
|
| Others |
0 (0%) |
1 (0.2%) |
0 (0%) |
|
| Unknown |
0 (0%) |
13 (2.3%) |
1 (2.9%) |
|
| Drug use |
|
|
|
|
| Current |
6 (13%) |
32 (6.6%) |
6 (19%) |
|
| None |
37 (80%) |
368 (76%) |
20 (63%) |
|
| Past |
0 (0%) |
44 (9.0%) |
1 (3.1%) |
|
| Sometimes |
1 (2.2%) |
12 (2.5%) |
4 (13%) |
|
| Substitution |
0 (0%) |
2 (0.4%) |
0 (0%) |
|
| Unknown |
2 (4.3%) |
29 (6.0%) |
1 (3.1%) |
|
| Baseline HIV RNA level (log10) |
4.69 (4.01, 5.21) |
4.67 (4.06, 5.16) |
4.75 (4.40, 5.17) |
0.8 |
| Baseline CD4 count |
349 (288, 491) |
323 (132, 486) |
448 (295, 575) |
0.013 |
Auvergne-Rhône-Alpes
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 37/303, i.e. 12%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 219 distinct clusters including 6% of local clusters ( 1 400%
).
Demographics by clustering status
| Characteristic |
Overall
N = 303 |
Clusters size ≥3
N = 23 |
Dyads
N = 14 |
Singletons
N = 266 |
p-value |
| sex |
|
|
|
|
0.011 |
| Female |
98 (32%) |
1 (4.3%) |
5 (36%) |
92 (35%) |
|
| Male |
204 (67%) |
22 (96%) |
9 (64%) |
173 (65%) |
|
| Transgender M/F |
1 (0.3%) |
0 (0%) |
0 (0%) |
1 (0.4%) |
|
| Age |
49 (38, 58) |
44 (35, 52) |
40 (31, 48) |
50 (39, 59) |
0.005 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
4 (1.3%) |
0 (0%) |
0 (0%) |
4 (1.5%) |
|
| ≥25-<35 |
47 (16%) |
4 (17%) |
5 (36%) |
38 (14%) |
|
| ≥35-<45 |
75 (25%) |
8 (35%) |
4 (29%) |
63 (24%) |
|
| ≥45-<55 |
77 (25%) |
7 (30%) |
5 (36%) |
65 (24%) |
|
| ≥55-<80 |
95 (31%) |
4 (17%) |
0 (0%) |
91 (34%) |
|
| ≥80 |
5 (1.7%) |
0 (0%) |
0 (0%) |
5 (1.9%) |
|
| WHO region (origin) |
|
|
|
|
0.4 |
| WHO Africa |
65 (22%) |
1 (4.5%) |
3 (21%) |
61 (24%) |
|
| WHO Americas |
9 (3.1%) |
0 (0%) |
1 (7.1%) |
8 (3.1%) |
|
| WHO Eastern Mediterranean |
5 (1.7%) |
0 (0%) |
0 (0%) |
5 (2.0%) |
|
| WHO Europe |
209 (72%) |
21 (95%) |
10 (71%) |
178 (70%) |
|
| WHO South-East Asia |
1 (0.3%) |
0 (0%) |
0 (0%) |
1 (0.4%) |
|
| WHO Western Pacific |
2 (0.7%) |
0 (0%) |
0 (0%) |
2 (0.8%) |
|
| Primo-infection |
|
|
|
|
0.3 |
| Non |
255 (84%) |
17 (74%) |
13 (93%) |
225 (85%) |
|
| Oui |
48 (16%) |
6 (26%) |
1 (7.1%) |
41 (15%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
24 (7.9%) |
5 (22%) |
0 (0%) |
19 (7.1%) |
|
| Blood |
6 (2.0%) |
0 (0%) |
0 (0%) |
6 (2.3%) |
|
| Heterosexual |
127 (42%) |
2 (8.7%) |
6 (43%) |
119 (45%) |
|
| IDU |
8 (2.6%) |
0 (0%) |
0 (0%) |
8 (3.0%) |
|
| Mother to child transmission |
9 (3.0%) |
0 (0%) |
0 (0%) |
9 (3.4%) |
|
| MSM |
117 (39%) |
16 (70%) |
8 (57%) |
93 (35%) |
|
| Others |
1 (0.3%) |
0 (0%) |
0 (0%) |
1 (0.4%) |
|
| Unknown |
11 (3.6%) |
0 (0%) |
0 (0%) |
11 (4.1%) |
|
| Drug use |
|
|
|
|
0.3 |
| Current |
40 (14%) |
6 (27%) |
2 (14%) |
32 (13%) |
|
| None |
190 (66%) |
11 (50%) |
10 (71%) |
169 (67%) |
|
| Past |
36 (13%) |
1 (4.5%) |
2 (14%) |
33 (13%) |
|
| Sometimes |
8 (2.8%) |
2 (9.1%) |
0 (0%) |
6 (2.4%) |
|
| Substitution |
4 (1.4%) |
0 (0%) |
0 (0%) |
4 (1.6%) |
|
| Unknown |
10 (3.5%) |
2 (9.1%) |
0 (0%) |
8 (3.2%) |
|
| Baseline HIV RNA level (log10) |
4.65 (3.98, 5.26) |
4.77 (4.16, 5.66) |
4.33 (4.08, 4.34) |
4.67 (3.85, 5.27) |
0.4 |
| Baseline CD4 count |
442 (270, 638) |
639 (531, 778) |
517 (431, 609) |
417 (258, 618) |
0.015 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 266 |
Not Growing
N = 36 |
Growing
N = 1 |
p-value |
| sex |
|
|
|
0.11 |
| Female |
92 (35%) |
6 (17%) |
0 (0%) |
|
| Male |
173 (65%) |
30 (83%) |
1 (100%) |
|
| Transgender M/F |
1 (0.4%) |
0 (0%) |
0 (0%) |
|
| Age |
50 (39, 59) |
40 (35, 49) |
63 (63, 63) |
0.002 |
| Age group |
|
|
|
0.023 |
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
4 (1.5%) |
0 (0%) |
0 (0%) |
|
| ≥25-<35 |
38 (14%) |
9 (25%) |
0 (0%) |
|
| ≥35-<45 |
63 (24%) |
12 (33%) |
0 (0%) |
|
| ≥45-<55 |
65 (24%) |
12 (33%) |
0 (0%) |
|
| ≥55-<80 |
91 (34%) |
3 (8.3%) |
1 (100%) |
|
| ≥80 |
5 (1.9%) |
0 (0%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
0.6 |
| WHO Africa |
61 (24%) |
4 (11%) |
0 (0%) |
|
| WHO Americas |
8 (3.1%) |
1 (2.9%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
5 (2.0%) |
0 (0%) |
0 (0%) |
|
| WHO Europe |
178 (70%) |
30 (86%) |
1 (100%) |
|
| WHO South-East Asia |
1 (0.4%) |
0 (0%) |
0 (0%) |
|
| WHO Western Pacific |
2 (0.8%) |
0 (0%) |
0 (0%) |
|
| Primo-infection |
|
|
|
0.2 |
| Non |
225 (85%) |
30 (83%) |
0 (0%) |
|
| Oui |
41 (15%) |
6 (17%) |
1 (100%) |
|
| Transmission risk |
|
|
|
0.041 |
| Bisexual |
19 (7.1%) |
5 (14%) |
0 (0%) |
|
| Blood |
6 (2.3%) |
0 (0%) |
0 (0%) |
|
| Heterosexual |
119 (45%) |
8 (22%) |
0 (0%) |
|
| IDU |
8 (3.0%) |
0 (0%) |
0 (0%) |
|
| Mother to child transmission |
9 (3.4%) |
0 (0%) |
0 (0%) |
|
| MSM |
93 (35%) |
23 (64%) |
1 (100%) |
|
| Others |
1 (0.4%) |
0 (0%) |
0 (0%) |
|
| Unknown |
11 (4.1%) |
0 (0%) |
0 (0%) |
|
| Drug use |
|
|
|
0.5 |
| Current |
32 (13%) |
8 (23%) |
0 (0%) |
|
| None |
169 (67%) |
20 (57%) |
1 (100%) |
|
| Past |
33 (13%) |
3 (8.6%) |
0 (0%) |
|
| Sometimes |
6 (2.4%) |
2 (5.7%) |
0 (0%) |
|
| Substitution |
4 (1.6%) |
0 (0%) |
0 (0%) |
|
| Unknown |
8 (3.2%) |
2 (5.7%) |
0 (0%) |
|
| Baseline HIV RNA level (log10) |
4.67 (3.85, 5.27) |
4.42 (4.15, 5.26) |
4.88 (4.88, 4.88) |
>0.9 |
| Baseline CD4 count |
417 (258, 618) |
581 (442, 758) |
687 (687, 687) |
0.015 |
Table of cluster dispersal
| Characteristic |
local only
N = 14 |
Not clustering
N = 266 |
spread
N = 23 |
p-value |
| sex |
|
|
|
0.2 |
| Female |
2 (14%) |
92 (35%) |
4 (17%) |
|
| Male |
12 (86%) |
173 (65%) |
19 (83%) |
|
| Transgender M/F |
0 (0%) |
1 (0.4%) |
0 (0%) |
|
| Age |
48 (35, 52) |
50 (39, 59) |
40 (34, 45) |
0.005 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
0 (0%) |
4 (1.5%) |
0 (0%) |
|
| ≥25-<35 |
3 (21%) |
38 (14%) |
6 (26%) |
|
| ≥35-<45 |
3 (21%) |
63 (24%) |
9 (39%) |
|
| ≥45-<55 |
6 (43%) |
65 (24%) |
6 (26%) |
|
| ≥55-<80 |
2 (14%) |
91 (34%) |
2 (8.7%) |
|
| ≥80 |
0 (0%) |
5 (1.9%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
0.5 |
| WHO Africa |
0 (0%) |
61 (24%) |
4 (18%) |
|
| WHO Americas |
0 (0%) |
8 (3.1%) |
1 (4.5%) |
|
| WHO Eastern Mediterranean |
0 (0%) |
5 (2.0%) |
0 (0%) |
|
| WHO Europe |
14 (100%) |
178 (70%) |
17 (77%) |
|
| WHO South-East Asia |
0 (0%) |
1 (0.4%) |
0 (0%) |
|
| WHO Western Pacific |
0 (0%) |
2 (0.8%) |
0 (0%) |
|
| Primo-infection |
|
|
|
0.4 |
| Non |
10 (71%) |
225 (85%) |
20 (87%) |
|
| Oui |
4 (29%) |
41 (15%) |
3 (13%) |
|
| Transmission risk |
|
|
|
0.2 |
| Bisexual |
2 (14%) |
19 (7.1%) |
3 (13%) |
|
| Blood |
0 (0%) |
6 (2.3%) |
0 (0%) |
|
| Heterosexual |
2 (14%) |
119 (45%) |
6 (26%) |
|
| IDU |
0 (0%) |
8 (3.0%) |
0 (0%) |
|
| Mother to child transmission |
0 (0%) |
9 (3.4%) |
0 (0%) |
|
| MSM |
10 (71%) |
93 (35%) |
14 (61%) |
|
| Others |
0 (0%) |
1 (0.4%) |
0 (0%) |
|
| Unknown |
0 (0%) |
11 (4.1%) |
0 (0%) |
|
| Drug use |
|
|
|
0.3 |
| Current |
2 (14%) |
32 (13%) |
6 (27%) |
|
| None |
11 (79%) |
169 (67%) |
10 (45%) |
|
| Past |
1 (7.1%) |
33 (13%) |
2 (9.1%) |
|
| Sometimes |
0 (0%) |
6 (2.4%) |
2 (9.1%) |
|
| Substitution |
0 (0%) |
4 (1.6%) |
0 (0%) |
|
| Unknown |
0 (0%) |
8 (3.2%) |
2 (9.1%) |
|
| Baseline HIV RNA level (log10) |
4.50 (4.15, 5.44) |
4.67 (3.85, 5.27) |
4.46 (4.17, 4.99) |
0.9 |
| Baseline CD4 count |
580 (517, 667) |
417 (258, 618) |
637 (414, 789) |
0.018 |
Martinique
Clustering rate
The overall clustering rate with a genetic distance threshold
of 0.5% is 174/922, i.e. 19%.
Cluster size and composition
With a genetic distance threshold of 0.5% , we
identified 299 distinct clusters including 39% of local clusters ( 11
800% ).
Demographics by clustering status
| Characteristic |
Overall
N = 922 |
Clusters size ≥3
N = 99 |
Dyads
N = 75 |
Singletons
N = 748 |
p-value |
| sex |
|
|
|
|
0.12 |
| Female |
318 (34%) |
27 (27%) |
20 (27%) |
271 (36%) |
|
| Male |
599 (65%) |
72 (73%) |
54 (72%) |
473 (63%) |
|
| Transgender M/F |
5 (0.5%) |
0 (0%) |
1 (1.3%) |
4 (0.5%) |
|
| Age |
53 (40, 63) |
37 (30, 53) |
45 (33, 56) |
55 (43, 64) |
<0.001 |
| Age group |
|
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
32 (3.5%) |
10 (10%) |
7 (9.3%) |
15 (2.0%) |
|
| ≥25-<35 |
123 (13%) |
34 (34%) |
14 (19%) |
75 (10%) |
|
| ≥35-<45 |
145 (16%) |
18 (18%) |
14 (19%) |
113 (15%) |
|
| ≥45-<55 |
182 (20%) |
15 (15%) |
17 (23%) |
150 (20%) |
|
| ≥55-<80 |
413 (45%) |
22 (22%) |
23 (31%) |
368 (49%) |
|
| ≥80 |
27 (2.9%) |
0 (0%) |
0 (0%) |
27 (3.6%) |
|
| WHO region (origin) |
|
|
|
|
0.004 |
| WHO Africa |
13 (1.5%) |
0 (0%) |
4 (5.6%) |
9 (1.2%) |
|
| WHO Americas |
121 (14%) |
5 (5.3%) |
9 (13%) |
107 (15%) |
|
| WHO Eastern Mediterranean |
2 (0.2%) |
1 (1.1%) |
0 (0%) |
1 (0.1%) |
|
| WHO Europe |
751 (85%) |
88 (94%) |
59 (82%) |
604 (84%) |
|
| Primo-infection |
|
|
|
|
<0.001 |
| Non |
851 (92%) |
80 (81%) |
66 (88%) |
705 (94%) |
|
| Oui |
71 (7.7%) |
19 (19%) |
9 (12%) |
43 (5.7%) |
|
| Transmission risk |
|
|
|
|
|
| Bisexual |
126 (14%) |
22 (22%) |
11 (15%) |
93 (12%) |
|
| Blood |
9 (1.0%) |
1 (1.0%) |
0 (0%) |
8 (1.1%) |
|
| Heterosexual |
588 (64%) |
50 (51%) |
32 (43%) |
506 (68%) |
|
| IDU |
14 (1.5%) |
1 (1.0%) |
4 (5.3%) |
9 (1.2%) |
|
| Mother to child transmission |
3 (0.3%) |
0 (0%) |
0 (0%) |
3 (0.4%) |
|
| MSM |
169 (18%) |
25 (25%) |
27 (36%) |
117 (16%) |
|
| Others |
1 (0.1%) |
0 (0%) |
1 (1.3%) |
0 (0%) |
|
| Unknown |
12 (1.3%) |
0 (0%) |
0 (0%) |
12 (1.6%) |
|
| Drug use |
|
|
|
|
|
| Current |
108 (13%) |
18 (20%) |
7 (10%) |
83 (12%) |
|
| None |
595 (70%) |
54 (60%) |
45 (65%) |
496 (71%) |
|
| Past |
124 (14%) |
14 (16%) |
13 (19%) |
97 (14%) |
|
| Sometimes |
16 (1.9%) |
4 (4.4%) |
1 (1.4%) |
11 (1.6%) |
|
| Substitution |
4 (0.5%) |
0 (0%) |
1 (1.4%) |
3 (0.4%) |
|
| Unknown |
9 (1.1%) |
0 (0%) |
2 (2.9%) |
7 (1.0%) |
|
| Baseline HIV RNA level (log10) |
4.53 (3.94, 5.10) |
4.37 (4.04, 5.05) |
4.44 (3.96, 5.06) |
4.55 (3.93, 5.13) |
0.5 |
| Baseline CD4 count |
393 (208, 572) |
452 (317, 629) |
417 (246, 653) |
378 (187, 556) |
0.007 |
New clustering individuals
Table of growing clusters
| Characteristic |
Not Clustering
N = 748 |
Not Growing
N = 159 |
Growing
N = 15 |
p-value |
| sex |
|
|
|
0.093 |
| Female |
271 (36%) |
41 (26%) |
6 (40%) |
|
| Male |
473 (63%) |
117 (74%) |
9 (60%) |
|
| Transgender M/F |
4 (0.5%) |
1 (0.6%) |
0 (0%) |
|
| Age |
55 (43, 64) |
38 (30, 53) |
62 (51, 67) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
15 (2.0%) |
17 (11%) |
0 (0%) |
|
| ≥25-<35 |
75 (10%) |
48 (30%) |
0 (0%) |
|
| ≥35-<45 |
113 (15%) |
32 (20%) |
0 (0%) |
|
| ≥45-<55 |
150 (20%) |
27 (17%) |
5 (33%) |
|
| ≥55-<80 |
368 (49%) |
35 (22%) |
10 (67%) |
|
| ≥80 |
27 (3.6%) |
0 (0%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
0.11 |
| WHO Africa |
9 (1.2%) |
4 (2.6%) |
0 (0%) |
|
| WHO Americas |
107 (15%) |
14 (9.2%) |
0 (0%) |
|
| WHO Eastern Mediterranean |
1 (0.1%) |
1 (0.7%) |
0 (0%) |
|
| WHO Europe |
604 (84%) |
133 (88%) |
14 (100%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
705 (94%) |
132 (83%) |
14 (93%) |
|
| Oui |
43 (5.7%) |
27 (17%) |
1 (6.7%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
93 (12%) |
31 (19%) |
2 (13%) |
|
| Blood |
8 (1.1%) |
1 (0.6%) |
0 (0%) |
|
| Heterosexual |
506 (68%) |
70 (44%) |
12 (80%) |
|
| IDU |
9 (1.2%) |
4 (2.5%) |
1 (6.7%) |
|
| Mother to child transmission |
3 (0.4%) |
0 (0%) |
0 (0%) |
|
| MSM |
117 (16%) |
52 (33%) |
0 (0%) |
|
| Others |
0 (0%) |
1 (0.6%) |
0 (0%) |
|
| Unknown |
12 (1.6%) |
0 (0%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
83 (12%) |
24 (17%) |
1 (6.7%) |
|
| None |
496 (71%) |
88 (61%) |
11 (73%) |
|
| Past |
97 (14%) |
24 (17%) |
3 (20%) |
|
| Sometimes |
11 (1.6%) |
5 (3.5%) |
0 (0%) |
|
| Substitution |
3 (0.4%) |
1 (0.7%) |
0 (0%) |
|
| Unknown |
7 (1.0%) |
2 (1.4%) |
0 (0%) |
|
| Baseline HIV RNA level (log10) |
4.55 (3.93, 5.13) |
4.35 (3.92, 4.99) |
4.83 (4.14, 5.47) |
0.13 |
| Baseline CD4 count |
378 (187, 556) |
429 (305, 636) |
373 (267, 599) |
0.009 |
Table of cluster dispersal
| Characteristic |
local only
N = 118 |
Not clustering
N = 748 |
spread
N = 56 |
p-value |
| sex |
|
|
|
0.11 |
| Female |
29 (25%) |
271 (36%) |
18 (32%) |
|
| Male |
88 (75%) |
473 (63%) |
38 (68%) |
|
| Transgender M/F |
1 (0.8%) |
4 (0.5%) |
0 (0%) |
|
| Age |
40 (31, 56) |
55 (43, 64) |
42 (30, 55) |
<0.001 |
| Age group |
|
|
|
|
| <15 |
0 (0%) |
0 (0%) |
0 (0%) |
|
| ≥15-<25 |
8 (6.8%) |
15 (2.0%) |
9 (16%) |
|
| ≥25-<35 |
37 (31%) |
75 (10%) |
11 (20%) |
|
| ≥35-<45 |
21 (18%) |
113 (15%) |
11 (20%) |
|
| ≥45-<55 |
21 (18%) |
150 (20%) |
11 (20%) |
|
| ≥55-<80 |
31 (26%) |
368 (49%) |
14 (25%) |
|
| ≥80 |
0 (0%) |
27 (3.6%) |
0 (0%) |
|
| WHO region (origin) |
|
|
|
0.014 |
| WHO Africa |
3 (2.6%) |
9 (1.2%) |
1 (2.0%) |
|
| WHO Americas |
13 (11%) |
107 (15%) |
1 (2.0%) |
|
| WHO Eastern Mediterranean |
0 (0%) |
1 (0.1%) |
1 (2.0%) |
|
| WHO Europe |
99 (86%) |
604 (84%) |
48 (94%) |
|
| Primo-infection |
|
|
|
<0.001 |
| Non |
97 (82%) |
705 (94%) |
49 (88%) |
|
| Oui |
21 (18%) |
43 (5.7%) |
7 (13%) |
|
| Transmission risk |
|
|
|
|
| Bisexual |
24 (20%) |
93 (12%) |
9 (16%) |
|
| Blood |
0 (0%) |
8 (1.1%) |
1 (1.8%) |
|
| Heterosexual |
54 (46%) |
506 (68%) |
28 (50%) |
|
| IDU |
3 (2.5%) |
9 (1.2%) |
2 (3.6%) |
|
| Mother to child transmission |
0 (0%) |
3 (0.4%) |
0 (0%) |
|
| MSM |
36 (31%) |
117 (16%) |
16 (29%) |
|
| Others |
1 (0.8%) |
0 (0%) |
0 (0%) |
|
| Unknown |
0 (0%) |
12 (1.6%) |
0 (0%) |
|
| Drug use |
|
|
|
|
| Current |
18 (17%) |
83 (12%) |
7 (13%) |
|
| None |
62 (58%) |
496 (71%) |
37 (70%) |
|
| Past |
18 (17%) |
97 (14%) |
9 (17%) |
|
| Sometimes |
5 (4.7%) |
11 (1.6%) |
0 (0%) |
|
| Substitution |
1 (0.9%) |
3 (0.4%) |
0 (0%) |
|
| Unknown |
2 (1.9%) |
7 (1.0%) |
0 (0%) |
|
| Baseline HIV RNA level (log10) |
4.35 (3.92, 5.05) |
4.55 (3.93, 5.13) |
4.64 (4.07, 5.08) |
0.4 |
| Baseline CD4 count |
420 (288, 617) |
378 (187, 556) |
449 (310, 643) |
0.009 |